RMAM
PGNX

Raab & Moskowitz Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Raab & Moskowitz Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-200
Closed -$1K – 561
2019
Q4 		$1K Buy
+200
New +$1.06K ﹤0.01% 530

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Raab & Moskowitz Asset Management's PGNX Position: Q1 2020 in Review

Raab & Moskowitz Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2020, closing a stake of 200 shares — an estimated $1K sold.

Raab & Moskowitz Asset Management first reported a position in PGNX in Q4 2019 and held it in 1 quarter. The position peaked at $1K in Q4 2019. 129 funds tracked by Wall St. Rank hold PGNX as of Q1 2020.

  • Raab & Moskowitz Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2020 after selling out during the quarter.
  • Raab & Moskowitz Asset Management sold 200 Progenics Pharmaceuticals Inc shares in Q1 2020, an estimated $1K.
  • Raab & Moskowitz Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q4 2019 and held it in 1 quarter.
  • Raab & Moskowitz Asset Management's Progenics Pharmaceuticals Inc position peaked at $1K in Q4 2019.
  • 129 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2020.

Based on Raab & Moskowitz Asset Management's 13F filing for Q1 2020, filed 14 May 2020.